Get the Stockscreener App
74.39
1.42%
1.225
Dexcom Inc stock is traded at $74.39, with a volume of 1.81M.
It is up +1.42% in the last 24 hours and up +1.17% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$73.16
Open:
$73.45
24h Volume:
1.81M
Relative Volume:
0.35
Market Cap:
$28.60B
Revenue:
$4.66B
Net Income/Loss:
$836.30M
P/E Ratio:
35.54
EPS:
2.093
Net Cash Flow:
$1.08B
1W Performance:
+2.67%
1M Performance:
+1.17%
6M Performance:
-2.53%
1Y Performance:
-17.48%
1-Day Range:
$72.83
$74.34
1-Week Range:
$70.81
$74.49
52-Week Range:
$54.11
$90.00
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
74.31 | 28.16B | 4.66B | 836.30M | 1.08B | 2.093 |
|
ABT
Abbott Laboratories
|
116.22 | 199.55B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
386.19 | 146.96B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
97.02 | 123.91B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
75.66 | 109.04B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.78 | 48.40B | 6.07B | 1.06B | 799.60M | 1.8527 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DexCom Weighs GLP 1 CGM Tailwind Against Valuation And Momentum Signals - Yahoo Finance
HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - Morningstar
Assessing DexCom (DXCM) Valuation After Short Term Gains And A 14.5% Undervaluation Narrative - simplywall.st
Got $10,000? I Think DexCom Stock Could Be a Quiet Winner of the GLP‑1 Wars - The Globe and Mail
Got $10,000? I Think DexCom Stock Could Be a Quiet Winner of the GLP‑1 Wars - The Motley Fool
Dexcom announces upcoming conference presentation - marketscreener.com
Dexcom Announces Upcoming Conference Presentation - The Joplin Globe
Mizuho Raises DexCom (DXCM) Price Target to $90 from $78 After Earnings Beat - Finviz
Mizuho raises DexCom (DXCM) price target to $90 from $78 after earnings beat - MSN
I Tried Dexcom’s Stelo, a Glucose Biosensor, for 30 Days. Here’s What I Learned - Athletech News
I Tried Dexcom’s Stelo Glucose Biosensor for 30 Days. Here’s What I Learned - Athletech News
DexCom: How Product Innovation and Feature Adoption Are Expanding Its Diabetes Opportunity! - Smartkarma
Dexcom’s CEO to Chair AdvaMed’s Diabetes Sector - Medical Product Outsourcing
DexCom, Inc. (DXCM) Continues to Focus on Glucose Sensors Leadership - Insider Monkey
DexCom, Inc. (DXCM): Investor Outlook Highlights 16.94% Upside Potential and Strong Buy Ratings - DirectorsTalk Interviews
Is DexCom Inc. a strong growth stockJuly 2025 Opening Moves & Long Hold Capital Preservation Tips - mfd.ru
DexCom G7 Rollout And Expansion Shape Growth And Competitive Outlook - Sahm
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term - Yahoo Finance
SENS Eversense 365 Integrated With twiist Gains Full Availability - TradingView
The 5 Most Interesting Analyst Questions From DexCom’s Q4 Earnings Call - The Globe and Mail
The Strong Earnings Posted By DexCom (NASDAQ:DXCM) Are A Good Indication Of The Strength Of The Business - simplywall.st
The 5 Most Interesting Analyst Questions From DexCom's Q4 Earnings Call - Finviz
P/E Ratio Insights for DexCom - Benzinga
NEOS Investment Management LLC Boosts Position in DexCom, Inc. $DXCM - Defense World
What Wall Street predicts for DexCom Inc. stock pricePortfolio Gains Summary & Free Real-Time Volume Trigger Notifications - mfd.ru
Dexcom G6 Glucose Monitor Lawsuit Claims Manufacturer’s Device Modifications Resulted in Teen’s Death - AboutLawsuits.com
Dexcom Stock After Volatility: Is This High-Growth Medtech Now Mispriced? - AD HOC NEWS
What DexCom (DXCM)'s Margin Beat And Reaffirmed 2026 Outlook Means For Shareholders - simplywall.st
The DexCom, Inc. (NASDAQ:DXCM) Yearly Results Are Out And Analysts Have Published New Forecasts - 富途牛牛
DexCom Inc. (DXCM) Reports Strong Performance While Maintaining Forward Outlook - Bitget
10 Best Medical Technology Stocks to Invest In - Insider Monkey
DexCom Earnings Call Highlights Margin Rebound, Growth - The Globe and Mail
Is DexCom Inc. in a consolidation phaseJuly 2025 Final Week & Weekly Breakout Watchlists - mfd.ru
DexCom (DXCM) Margin Expansion To 17.9% Reinforces Bullish Earnings Narratives - Sahm
DexCom’s AI Stelo Upgrade Faces Valuation Questions After Share Declines - Sahm
DexCom Expands G7 And Stelo To Deepen CGM Ecosystem Engagement - Yahoo Finance
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth - sharewise.com
DexCom (DXCM) Maintains Buy Rating Despite Lowered Price Target - GuruFocus
Key facts: DexCom reports $2.8B profit; Wells Fargo cuts price target - TradingView
Why Is DexCom (DXCM) Stock Rocketing Higher Today - Finviz
Dexcom reports 2025 revenues of $4.66bn yet 2026 outlook lags analyst expectations - Yahoo Finance
Dexcom seeks expanded Medicare coverage of CGMs for Type 2 diabetes - MedTech Dive
Barclays Updates Rating on DexCom (DXCM) with Slight Price Targe - GuruFocus
DexCom (NASDAQ:DXCM) Stock Price Up 8.4% on Earnings Beat - MarketBeat
Wells Fargo & Company Has Lowered Expectations for DexCom (NASDAQ:DXCM) Stock Price - MarketBeat
DXCM Q4 Deep Dive: New Product Launches and International Strategy Drive Outlook - Finviz
DexCom, Inc. (NASDAQ:DXCM) Q4 2025 Earnings Call Transcript - Insider Monkey
DexCom (NASDAQ:DXCM) Price Target Raised to $90.00 - MarketBeat
DexCom, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Bernstein Adjusts DexCom Price Target to $83 From $86, Maintains Outperform Rating - marketscreener.com
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):